Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat
07:02pm, Friday, 06'th May 2022 Zacks Investment Research
Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat
04:33pm, Friday, 06'th May 2022
Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
12:55pm, Thursday, 05'th May 2022 Zacks Investment Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -76.58% and 8.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
12:43pm, Thursday, 05'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
The�
Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2022 Results - Earnings Call Transcript
11:39am, Thursday, 05'th May 2022
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Ian Karp - SVP, IR & Corporate Communications John Leonard - President, CEO & Di
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
10:33am, Thursday, 05'th May 2022
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -76.58% and 8.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
07:19pm, Wednesday, 04'th May 2022 Zacks Investment Research
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
04:33pm, Wednesday, 04'th May 2022
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
Incyte (INCY) Lags Q1 Earnings and Revenue Estimates
12:25pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Incyte (INCY) delivered earnings and revenue surprises of -3.51% and 4%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference
11:30am, Monday, 02'nd May 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
02:09pm, Thursday, 28'th Apr 2022 Benzinga
Upgrades
According to Johnson Rice, the prior rating for RPC Inc (NYSE:RES) was changed from Hold to Accumulate. In the first quarter, RPC showed an EPS of $0.07, compared to $0.05 from the year-ago
4 Analysts Have This to Say About Intellia Therapeutics
01:15pm, Thursday, 28'th Apr 2022 Benzinga
Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
0
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates
11:30am, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutic
3 Top Biotech Stocks Ready for a Bull Run
11:40am, Wednesday, 20'th Apr 2022 The Motley Fool
The hype has died down. Now it's time for science to take over.
3 Top Biotech Stocks Ready for a Bull Run
07:40am, Wednesday, 20'th Apr 2022
The hype has died down. Now it's time for science to take over.
